Falco Jacopo, Cavallo Claudio, Vetrano Ignazio G, de Laurentis Camilla, Siozos Lampros, Schiariti Marco, Broggi Morgan, Ferroli Paolo, Acerbi Francesco
Department of Neurosurgery, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Department of Neurosurgery, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ, United States.
Front Surg. 2019 Aug 13;6:49. doi: 10.3389/fsurg.2019.00049. eCollection 2019.
Sodium fluorescein, a green, water soluble dye, is used as neurosurgical fluorescent tracer thanks to its property to accumulate in cerebral regions of blood-brain barrier (BBB) disruption. The authors report the preliminary results of a prospective observational study regarding the use of fluorescein-guided technique for the resection of suspected malignant neoplasms of the central nervous system (CNS), contrast enhancing at preoperative magnetic resonance imaging (MRI), using a dedicated filter on the surgical microscope. In March 2016 the authors started a prospective, observational trial to evaluate intraoperative fluorescence's characteristics of CNS tumors, the percentage of extent of resection thanks to fluorescein aid and side effects related to fluorescein administration. This report is based on a preliminary analysis of the results of first 279 enrolled patients. Fluorescein was intravenously injected after intubation or immediately at the entrance in the operating room for awake procedures; the tumor was removed using a dedicated filter on the surgical microscope in an inside-out fashion until all fluorescent tissue was removed, as considered feasible by the surgeon. The 279 patients finally enrolled in the trial, both firstly diagnosed and recurrent, were categorized according to WHO pathological classification and there were 212 neuroepithelial tumors, 25 brain metastases, 10 cerebral lymphomas, 7 hemangioblastomas, or hemangioendotheliomas and 25 other tumors and conditions. No adverse reaction related to the administration of fluorescein or to the combined use of fluorescein with other fluorophores was registered. Fluorescein accumulated in cerebral regions where the BBB was damaged, representing a significant surgical aid in most of the CNS tumors with contrast enhancement. In cases of complete removal of all fluorescent tissue, as intraoperatively judged by the surgeon, postoperative MRI revealed a gross total resection in 181/198 patients (91.4%). Based on these preliminary results, fluorescein-guided surgery with a dedicated filter on the microscope is a safe and effective technique to improve visualization and resection of different CNS tumors and conditions, based on BBB alteration.
荧光素钠是一种绿色的水溶性染料,因其能在血脑屏障(BBB)破坏的脑区蓄积的特性,被用作神经外科荧光示踪剂。作者报告了一项前瞻性观察性研究的初步结果,该研究使用手术显微镜上的专用滤光片,探讨荧光素引导技术在切除术前磁共振成像(MRI)显示有强化的疑似中枢神经系统(CNS)恶性肿瘤中的应用。2016年3月,作者启动了一项前瞻性观察性试验,以评估CNS肿瘤的术中荧光特征、荧光素辅助下的切除范围百分比以及与荧光素给药相关的副作用。本报告基于对首批279例入组患者结果的初步分析。在插管后或清醒手术进入手术室时立即静脉注射荧光素;使用手术显微镜上的专用滤光片以由内向外的方式切除肿瘤,直到外科医生认为可行的情况下切除所有荧光组织。最终纳入试验的279例患者,包括初诊和复发患者,根据世界卫生组织病理分类进行分类,其中有212例神经上皮肿瘤、25例脑转移瘤、10例脑淋巴瘤、7例血管母细胞瘤或血管内皮细胞瘤以及25例其他肿瘤和病症。未记录到与荧光素给药或荧光素与其他荧光团联合使用相关的不良反应。荧光素在血脑屏障受损的脑区蓄积,对大多数有强化的CNS肿瘤而言是一种重要的手术辅助手段。在外科医生术中判断为完全切除所有荧光组织的病例中,术后MRI显示181/198例患者(91.4%)实现了大体全切。基于这些初步结果,使用显微镜上的专用滤光片进行荧光素引导手术是一种安全有效的技术,可基于血脑屏障改变改善不同CNS肿瘤和病症的可视化及切除效果。